Ovari Attila, Bicker Ilona, Machmueller Susann, Schuldt Tobias, Sauer Martin, Soltesz Stefan, Noeldge-Schomburg Gabriele, Mlynski Robert, Mencke Thomas
1 Department of Otorhinolaryngology, Rostock Medical University Center, Rostock, Germany.
2 Department of Anaesthesia and Intensive Care Medicine, Rostock Medical University Center, Rostock, Germany.
J Int Med Res. 2017 Jun;45(3):1098-1108. doi: 10.1177/0300060517701355. Epub 2017 Apr 28.
Objective The overall intubation conditions after tracheal intubation with remifentanil, propofol, and sevoflurane at 1.0 minimum alveolar concentration (MAC) are worse than with rocuronium at 0.45 mg/kg. Therefore, we compared the intubation conditions and laryngeal morbidity (vocal cord injuries, hoarseness, and sore throat) with sevoflurane at 1.2 and 1.4 MAC versus 1.0 MAC. Methods In this prospective clinical trial, 90 patients were randomized to 3 groups: the sevoflurane 1.0, 1.2, and 1.4 MAC groups. At 3 min, tracheal intubation was performed and the patients' intubation conditions were assessed. The vocal cords were examined for injury by videolaryngoscopy. Additionally, the incidence and severity of laryngeal morbidity were compared between women and men. Results Acceptable intubation conditions were seen in 72% of the patients without significant differences between the groups. Overall, vocal cord injuries (oedema) occurred in three (4%) patients. Women reported sore throat more often than men (51% vs. 21%, respectively). Conclusions Intubation conditions were not improved with higher sevoflurane concentrations. The incidence and severity of sore throat were greater in women than men.
ClinicalTrials.Gov: NCT 01896245.
目的 瑞芬太尼、丙泊酚和七氟醚在1.0最低肺泡浓度(MAC)下气管插管后的总体插管条件比罗库溴铵在0.45mg/kg时更差。因此,我们比较了七氟醚在1.2MAC和1.4MAC与1.0MAC时的插管条件及喉部发病率(声带损伤、声音嘶哑和咽痛)。方法 在这项前瞻性临床试验中,90例患者被随机分为3组:七氟醚1.0MAC组、1.2MAC组和1.4MAC组。3分钟时进行气管插管,并评估患者的插管条件。通过视频喉镜检查声带是否损伤。此外,比较了女性和男性之间喉部发病率的发生率和严重程度。结果 72%的患者插管条件可接受,组间无显著差异。总体而言,3例(4%)患者发生声带损伤(水肿)。女性咽痛的报告比男性更频繁(分别为51%和21%)。结论 更高的七氟醚浓度并未改善插管条件。女性咽痛的发生率和严重程度高于男性。
ClinicalTrials.Gov:NCT 01896245。